Medigene AG (MDG1.DE)
EUR 1.08
(-1.64%)
EUR 1.08
(-1.64%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.17 Million EUR | -94.2% |
| 2022 | -8.33 Million EUR | 16.56% |
| 2021 | -9.98 Million EUR | 65.43% |
| 2020 | -28.87 Million EUR | -44.65% |
| 2019 | -19.96 Million EUR | -17.09% |
| 2018 | -17.04 Million EUR | -25.61% |
| 2017 | -13.57 Million EUR | -42.99% |
| 2016 | -9.49 Million EUR | 26.98% |
| 2015 | -12.99 Million EUR | -125.79% |
| 2014 | -5.75 Million EUR | 44.01% |
| 2013 | -10.28 Million EUR | -4.29% |
| 2012 | -9.85 Million EUR | -256.97% |
| 2011 | 6.28 Million EUR | 135.15% |
| 2010 | -17.86 Million EUR | 18.64% |
| 2009 | -21.96 Million EUR | 28.67% |
| 2008 | -30.79 Million EUR | -3.06% |
| 2007 | -29.87 Million EUR | -333.55% |
| 2006 | -6.89 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.36 Million EUR | 26.95% |
| 2024 Q2 | -4.08 Million EUR | -21.35% |
| 2023 Q3 | -4.6 Million EUR | -13.44% |
| 2023 FY | -16.17 Million EUR | -94.2% |
| 2023 Q4 | -4.6 Million EUR | 0.0% |
| 2023 Q1 | -3.48 Million EUR | 68.67% |
| 2023 Q2 | -4.05 Million EUR | -16.44% |
| 2022 Q4 | -11.12 Million EUR | 0.0% |
| 2022 Q1 | 6.95 Million EUR | 261.17% |
| 2022 Q2 | -2.39 Million EUR | -134.37% |
| 2022 Q3 | -11.12 Million EUR | -365.07% |
| 2022 FY | -8.33 Million EUR | 16.56% |
| 2021 FY | -9.98 Million EUR | 65.43% |
| 2021 Q3 | -2.15 Million EUR | 11.48% |
| 2021 Q2 | -2.43 Million EUR | 13.89% |
| 2021 Q4 | -4.31 Million EUR | -100.0% |
| 2021 Q1 | -2.83 Million EUR | 82.67% |
| 2020 Q4 | -16.34 Million EUR | -100.0% |
| 2020 FY | -28.87 Million EUR | -44.65% |
| 2020 Q2 | -5.9 Million EUR | 5.76% |
| 2020 Q3 | -8.17 Million EUR | -38.34% |
| 2020 Q1 | -6.26 Million EUR | -21710.34% |
| 2019 Q2 | -8.61 Million EUR | -51.78% |
| 2019 Q4 | 29 Thousand EUR | 100.51% |
| 2019 FY | -19.96 Million EUR | -17.09% |
| 2019 Q1 | -5.67 Million EUR | -16.13% |
| 2019 Q3 | -5.7 Million EUR | 33.78% |
| 2018 FY | -17.04 Million EUR | -25.61% |
| 2018 Q1 | -3.55 Million EUR | -23.14% |
| 2018 Q4 | -4.88 Million EUR | 0.61% |
| 2018 Q3 | -4.91 Million EUR | -32.97% |
| 2018 Q2 | -3.69 Million EUR | -4.14% |
| 2017 Q4 | -2.88 Million EUR | 10.47% |
| 2017 Q3 | -3.22 Million EUR | 15.11% |
| 2017 Q2 | -3.79 Million EUR | -3.13% |
| 2017 Q1 | -3.67 Million EUR | 2.36% |
| 2017 FY | -13.57 Million EUR | -42.99% |
| 2016 Q1 | -1.38 Million EUR | 43.27% |
| 2016 FY | -9.49 Million EUR | 26.98% |
| 2016 Q2 | 986 Thousand EUR | 171.09% |
| 2016 Q4 | -3.76 Million EUR | 29.24% |
| 2016 Q3 | -5.32 Million EUR | -639.96% |
| 2015 FY | -12.99 Million EUR | -125.79% |
| 2015 Q4 | -2.44 Million EUR | 44.93% |
| 2015 Q3 | -4.44 Million EUR | -81.89% |
| 2015 Q2 | -2.44 Million EUR | 33.52% |
| 2015 Q1 | -3.67 Million EUR | -3149.56% |
| 2014 Q4 | -113 Thousand EUR | 95.97% |
| 2014 FY | -5.75 Million EUR | 44.01% |
| 2014 Q3 | -2.8 Million EUR | -251.82% |
| 2014 Q2 | -797 Thousand EUR | 61.01% |
| 2014 Q1 | -2.04 Million EUR | 19.97% |
| 2013 Q4 | -2.55 Million EUR | -23.26% |
| 2013 FY | -10.28 Million EUR | -4.29% |
| 2013 Q1 | -3.27 Million EUR | 56.24% |
| 2013 Q2 | -2.38 Million EUR | 27.16% |
| 2013 Q3 | -2.07 Million EUR | 13.09% |
| 2012 Q2 | 2.34 Million EUR | 202.99% |
| 2012 Q4 | -7.47 Million EUR | -209.56% |
| 2012 FY | -9.85 Million EUR | -256.97% |
| 2012 Q3 | -2.41 Million EUR | -202.98% |
| 2012 Q1 | -2.27 Million EUR | 72.02% |
| 2011 Q1 | 16.98 Million EUR | 275.7% |
| 2011 Q2 | -2.61 Million EUR | -115.41% |
| 2011 Q3 | 56 Thousand EUR | 102.14% |
| 2011 Q4 | -8.14 Million EUR | -14639.29% |
| 2011 FY | 6.28 Million EUR | 135.15% |
| 2010 Q4 | -9.66 Million EUR | -96.96% |
| 2010 Q2 | -959 Thousand EUR | 58.93% |
| 2010 Q3 | -4.9 Million EUR | -411.78% |
| 2010 Q1 | -2.33 Million EUR | 61.7% |
| 2010 FY | -17.86 Million EUR | 18.64% |
| 2009 Q2 | -6.38 Million EUR | -230.21% |
| 2009 Q4 | -6.09 Million EUR | 19.26% |
| 2009 Q3 | -7.55 Million EUR | -18.28% |
| 2009 FY | -21.96 Million EUR | 28.67% |
| 2009 Q1 | -1.93 Million EUR | 0.0% |
| 2008 FY | -30.79 Million EUR | -3.06% |
| 2007 FY | -29.87 Million EUR | -333.55% |
| 2006 FY | -6.89 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BioNTech SE | 930.3 Million EUR | 101.739% |
| CureVac N.V. | -260.16 Million EUR | 93.782% |
| Biotest Aktiengesellschaft | 127 Million EUR | 112.738% |
| Biotest Aktiengesellschaft | 127 Million EUR | 112.738% |
| BRAIN Biotech AG | -8.27 Million EUR | -95.398% |
| Formycon AG | 75.79 Million EUR | 121.343% |
| Heidelberg Pharma AG | -20.34 Million EUR | 20.492% |